Hyperexpression of Nerve Growth Factor in Patients with 2 Type Spinal Muscular Atrophy
Abstract
Key words: spinal muscle atrophy of type 2 (SMA), blood serum, nerve growth factor (NGF), compensatory-adaptive process.
Annotation: The article presents the results of complex clinical-laboratory study of 12 patients with II type spinal muscular atrophy (SMA). Features of neurotrophins’ changes were identified: concentration of nerve growth factor in blood serum of patients with 2 types SMA was significantly higher than in control group. The assumption is made that the overexpression of NGF is associated with the activity of compensatory-adaptive reactions aimed at the partial restoration of lost motor function in patients with SMA type 2. The identified features of neurotrophic regulation in patients with 2 type SMA should be taken into account at their treatment.
Volltext:
PDF (Russian)Literaturhinweise
Neurology - the national management: Under edition RAS academician Gusev E.I. Moscow, GJeOTAR-Media, 2009; 936. (in Russian)
Sokolova MG, Pennijajnen VA, Rezvancev MV, Lobzin SV, Aleksandrov NJu. Study of reinnervation process in patients with 2 type of spinal muscular atrophy: clinical experimental study: Vestnik SZGMU, Saint-Petersburg, 2014, Vol.6, No 4; 45−52. (in Russian)
Faller DM, Shilds D. Molecular cytobiology. Moscow, BINOM, 2006; 256. (in Russian)
Angelucci F, Peppe A, Carlesimo GA, Serafini F. A pilot study on the effect of cognitive training on BDNF serum levels in individuals with Parkinson's disease: Front Hum Neurosci, 2015, Vol.1; 231−243.
Blais M. Nerve growth factor, brain-derived neurotrophic factor, neurotrophin-3 and glial-derived neurotrophic factor enhance angiogenesis in a tissue-engineered in vitro model: Tissue Eng Part, 2013, №9; 55–64.
Davies AM. The role of neurotrophins in the developing nervous system: J. Neurobiol, 1994, V.25, № 11; 1134–1148.
Gurgis FM. Mitogen-activated protein kinase-activated protein kinase 2 in neuroinflammation, heat shock protein 27 phosphorylation, and cell cycle: role and targeting: J. Neurobiol, 2013, Vol.85, № 2; 145–156.
He YY, Zhang XY, Yung WH, Zhu JN, Wang JJ. Role of BDNF in central motor structures and motor diseases: Mol Neurobiol, 2013, Vol. 48(3); 83−93.
Huang E J. Neurotrophins. Roles in neuronal development and function: Annu. Rev. Neurosci, 2001, Vol.24; 677–736.
Levi-Montalchini R. The nerve growth factor. 35 years later: Science, 1987, Vol. 237; 1154−1162.
Penniyaynen VA, Sokolova MG. Correlation of level NGF and of results neurotrophic impact of blood serum of patients with spinal muscule atrophy of 2 type with the purpose of studying sprouting in organotypic tissue culture: Proceedings of the 1st Congress of the European Academy of Neurology. Berlin, 2015; 148−150.
Sokolova MG, Penniyaynen VA. Analyse des neurotrophen einflusses von blutserum der patienten mit spinaler muskelatrophie typ 2 auf wachstum der neuriten sensorischer ganglien: Proceedings of the 2nd European Conference on Biology and Medical Sciences. «East West» Association for Advanced Studies and Higher Education GmbH. Vienna, 2014; 112−117.
Sopova K. Dysregulation of neurotrophic and haematopoietic growth factors in Alzheimer's disease: from pathophysiology to novel treatment strategies:/ Alzheimer Res, 2013, №11; 27–29.
Van der Kolk NM, Speelman AD, van Nimwegen M, Kessels RP, Hakobjan M, Munneke M. BDNF polymorphism associates with decline in set shifting in Parkinson's disease: Neurobiol Aging, 2015, №36(3); 1605−1616.